Non-emergent hemoptysis in patients with primary or metastatic lung tumors: The role of transarterial embolization.

Autor: Geevarghese R; Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Petre E; Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ziv E; Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Santos E; Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rodriguez L; Department of Research and Technology Management, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zhao K; Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sotirchos VS; Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Solomon SB; Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Alexander ES; Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: alexane@mskcc.org.
Jazyk: angličtina
Zdroj: European journal of radiology [Eur J Radiol] 2024 Oct 12; Vol. 181, pp. 111786. Date of Electronic Publication: 2024 Oct 12.
DOI: 10.1016/j.ejrad.2024.111786
Abstrakt: Purpose: To evaluate the role of systemic arterial embolization for the management of non-emergent hemoptysis in patients with primary or metastatic lung tumors.
Materials and Methods: This is a retrospective single center study of consecutive patients who underwent systemic arterial embolization for non-emergent hemoptysis between 2011 and 2023. Study endpoints included technical success, clinical success (partial or complete resolution of hemoptysis) and overall survival. Hemoptysis-free and overall survival were estimated using the Kaplan-Meier method. Predictive factors for hemoptysis-free survival and overall survival were evaluated using univariate analysis (Cox regression). Post-procedural 30-day adverse events were recorded in line with Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Results: A total of 30 patients were identified. Technical success was achieved in 24/30 (80 %) patients. Clinical success following embolization was achieved in 23/30 (76.7 %) patients. Median length of hospitalization was 5 days (Range: 1 to 16 days). Median overall survival was 194 days (95 % CI: 89 to 258). Median hemoptysis-free survival was 286 days (95 % CI: 42 to not reached). No significant clinical or procedural predictors of hemoptysis-free survival or overall survival were identified. Serious adverse events (CTCAE Grade > 3) occurred in 1 patient (3.4 % - fatal respiratory failure).
Conclusion: Embolization of non-emergent hemoptysis in patients with lung malignancies is safe and effective. Recurrence is however high in this patient population, likely due to the nature of the underlying disease.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: E.A. is a paid consultant for Boston Scientific and reports leadership role in Society of Interventional Oncology. S.B.S. is a paid consultant for GE Healthcare, Merck and Obsidian; receives grants or contracts from GE Healthcare and Johnson & Johnson; and reports participation in data safety monitoring board of Candel Therapeutics and Impact Biotech, stock or stock options in Johnson & Johnson. E.Z. receives grant support from AACR-NETF, Memorial Sloan Kettering Cancer Center, Society of Interventional Radiology, Radiographic Society of North America, North American Neuroendocrine Tumor Society, Ethicon, Novartis and TOW Center.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: